Professional Documents
Culture Documents
NIOSOMES
Presented by
Rohan Aggarwal
(M Pharm sem II )
05/MPH/DIPSAR/18
Department of
Pharmaceutics
Contents
• Introduction
• Advantages
• Disadvantages
• Structure of niosomes
• Types of niosomes
• Comparision between liposomes & niosomes
• Composition of niosomes
• Factors affecting properties of niosomes
• Methods of Preparation
• Evaluation of niosomes
• Applications of niosomes
• Marketed preparations
Introduction
• Niosomes are a novel drug delivery system, in which the medication is encapsulated
in a vesicle composed of a bilayer of non-ionic surface active agents .
• They are structurally similar to liposomes in having a bilayer, however, the materials
used to prepare niosomes make them more stable and thus niosomes offer many more
advantages over liposomes.
• Physical Instability.
• Aggregation.
• Fusion.
• Leaking of entrapped drug.
• Hydrolysis of entrapped drug which limits the shelf life of the dispersion.
Structure
Niosomes are microscopic lamellar structures, which are formed
on the admixture of non-ionic surfactant of the alkyl or dialkyl
polyglycerol ether class and cholesterol with subsequent
hydration in aqueous media.
Niosomes may be unilamellar or multilamellar depending on the
method used to prepare them.
The hydrophilic ends are exposed on the outside and inside of
the vesicle, while the hydrophobic chains face each other within
the bilayer.
Hence, the vesicle holds hydrophilic drugs within the space
enclosed in the vesicle, while hydrophobic drugs are embedded
within the bilayer itself.
Figure 1: Structure of Niosomes
Types
1.Cholesterol
• Cholesterol is used to provide rigidity and proper shape, conformation to the niosomes
preparations.
• In the bilayer structure of niosomes, cholesterol forms hydrogen bonds with hydrophilic head
of a surfactant.
2. Nonionic surfactants
• Charged molecules increase the stability of the vesicles by the addition of charged groups the
bilayer of vesicles.
• They increase surface charge density and thereby prevent vesicles aggregation.
Factors Affecting Physico-Chemical Properties of Niosomes
1. Choice of surfactants:
• A surfactant used for preparation of niosomes must have a hydrophilic head and a hydrophobic tail.
• The hydrophobic tail may consist of one or two alkyl or perfluoroalkyl groups or, in some cases, a single
steroidal group.
• The ether-type surfactants with single-chain alkyl tail is more toxic than corresponding dialkyl ether
chain.
• The ester-type surfactants are chemically less stable than ether-type surfactants and the former is less
toxic than the latter due to ester-linked surfactant degraded by esterases to triglycerides and fatty acid in
vivo.
• The surfactants with alkyl chain length from C12 to C18 are suitable for preparation of noisome.
6. Method of preparation
• Different methods are used to prepare the niosomes suspension .
• Reverse phase evaporation method gives small size vesicles.
• Hand shaking method give larger vesicles than ether injection method.
• Niosomes prepared by transmembrane pH gradient method gives niosomes with greater entrapment
efficiency and better retention of entrapped drug.
Methods of preparation
• Injection method
• Thin Film hydration method
• Sonication
• Reverse phase evaporation
• The “Bubble” method
• Micro fluidization.
• Multiple membrane extrusion
• Transmembrane pH gradient drug uptake
• Formation of Niosomes from Proniosomes
1. Injection method
A) Ether injection method B) Ethanol injection method
• Ethanol injection method offers advantage that
• Slow injection of an ether solution of niosomal
it avoids both sonication and high pressure.
ingredients into an aqueous medium at high
• In this technique, surfactant dissolved in ethanol
temperature.
and forcefully injected in aqueous media using
• A mixture of surfactant and cholesterol is syringe.
dissolved in ether (20 ml) and injected into an • The whole system stirred using magnetic stirrer
aqueous phase (4 ml) using a 14- gauge needle in order to evaporate ethanol which results in
syringe 60 °C . formation of niosomal vesicles.
• Niosomes in the form of large unilamellar vesicles
(LUV) are formed.
(a) (b)
• In this method, mixture of cholesterol, non-ionic surfactant and dicetyl phosphate is solubilized in an
organic phase and further evaporated to produce transparent film.
• The film is dried in desiccator followed by hydration using aqueous phase containing drug.
• The whole system is then extruded via series of polycarbonate membranes (Figure 8).
• The resulting suspension contains vesicles of uniform size.
9. Stability studies
• To determine the stability of niosomes, the optimized batch was stored in airtight sealed vials at
different temperatures.
• Surface characteristics and percentage drug retained in niosomes and niosomes derived from
proniosomes were selected as parameters for evaluation of the stability, since instability of the
formulation would reflect in drug leakage and a decrease in the percentage drug retained.
• The niosomes were sampled at regular intervals of time (0,1,2 and 3 months ),observed for color
change, surface characteristics and tested for the percentage drug retained after being hydrated to form
niosomes and analyzed by suitable analytical methods(UV spectroscopy, HPLC methods etc).
Applications
1) Anti-neoplastic treatment
2) Leishmaniasis treatment
3) Studying immune response
4) Transdermal drug delivery system
5) Niosomes as drug carriers
6) Ophthalmic drug delivery
7) Drug targeting
1. Anti-neoplastic Treatment
• Doxorubicin, the anthracyclic antibiotic with broad spectrum anti-tumor activity, is formulated in
niosomal preparation for targeted delivery.
• Niosomal delivery of this drug to mice bearing S-180 tumor increased their life span and decreased the
rate of proliferation of sarcoma.
• Niosomal entrapment increased the half-life of the drug, prolonged its circulation and altered its
metabolism.
• Intravenous administration of methotrexate entrapped in niosomes to S-180 tumor bearing mice
resulted in total regression of tumor and also higher plasma level and slower elimination.
2. Leishmaniasis Treatment
• Leishmaniasis is a disease caused by parasite genus Leishmania which invades the cells of the liver and
spleen.
• Most Commonly prescribed drugs for the treatment are the derivatives of antimony – which, in higher
concentrations – can cause liver, cardiac and kidney damage.
• Use of niosomes as a drug carrier showed that it is possible to administer the drug at high levels without
the triggering the side effects, and thus showed greater efficacy in treatment.
3. Studying immune response
• Due to their immunological selectivity, low toxicity and greater stability; niosomes are being used to study
the nature of the immune response provoked by antigens.
• Non-ionic surfactant vesicles have clearly demonstrated their ability to function as adjuvants following
parenteral administration with a number of different antigens and peptides.
7. Drug Targeting
• Niosomes possess beneficial ability of targeting site of action.
• Targeting of drugs to reticulo-endothelial system (RES) is successfully done using niosomes.
• The RES holds up niosome vesicles and this uptake of niosomes is influenced by opsonins (circulating
serum factors). Opsonins render the niosome for clearance.
• This process of localization of active pharmaceutical ingredient can be useful in the treatment of cancer
cells, different parasitic infections and can also be applicable to target particular organ other than RES40.
TABLE 4: LIST OF NIOSOME FORMULATION
MARKETED PRODUCTS
• Lancome has come out with a variety of anti-ageing products which are based on
niosomes Formulations. Niosomes Preparation in the Market is – Lancôme
34